Ovarian cancer molecular stratification and tumour heterogeneity; a necessity and a challenge

Ovarian cancer molecular stratification and tumour heterogeneity; a necessity and a challenge

Bibliographic Details
Main Authors:	Stefan eSymeonides, Charlie eGourley
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2015-10-01
Series:	Frontiers in Oncology
Subjects:	stratification heterogeneity ovarian cancer bevacizumab olaparib
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00229/full

Similar Items

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
by: Angiolo Gadducci, et al.
Published: (2019-01-01)

Profile of olaparib in the treatment of advanced ovarian cancer
by: Chase DM, et al.
Published: (2016-04-01)

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
by: Soupos Nikolaos, et al.
Published: (2015-09-01)

The use of PARP inhibitor - olaparib for the treatment of ovarian cancer in clinical practice
by: S V Khokhlova
Published: (2016-12-01)

Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
by: S V Khokhlova
Published: (2017-09-01)

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
by: Montemorano L, et al.
Published: (2019-12-01)

CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: biomarker correlates from the randomized phase 2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer
by: Jung-Min eLee, et al.
Published: (2015-06-01)

Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
by: Giorgio Valabrega, et al.
Published: (2021-04-01)

Practical aspects of treating relapsed BRCA-associated ovarian cancer
by: A. A. Rumyantse, et al.
Published: (2019-12-01)

Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China
by: Jing Ni, et al.
Published: (2019-11-01)

Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
by: Longhui Zhong, et al.
Published: (2020-09-01)

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
by: Miriam K. Gomez, et al.
Published: (2020-06-01)

Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report
by: Li A, et al.
Published: (2018-06-01)

UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway
by: Wenjing Hu, et al.
Published: (2021-09-01)

Is it possible to improve primary therapy of advanced ovarian cancer?
by: S. V. Khokhlova
Published: (2020-07-01)

Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
by: Jing Ni, et al.
Published: (2020-03-01)

A case report of long term bevacizumab treatment in multiresistant ovarian cancer
by: Anette Kargo, et al.
Published: (2016-06-01)

Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials
by: Ma J, et al.
Published: (2019-04-01)

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
by: Jiang X, et al.
Published: (2019-05-01)

Olaparib in the maintenance treatment of platinum-sensitive relapse of BRCA mutant ovarian cancer in routine clinical practice: first results of observational study in Russian patients
by: E V Artamonova, et al.
Published: (2018-09-01)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
by: Lorusso D, et al.
Published: (2018-05-01)

Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review
by: Sudeep Gupta, et al.
Published: (2019-11-01)

Supportive therapy for ovarian cancer
by: I A Pokataev, et al.
Published: (2016-06-01)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
by: Yifan Jiang, et al.
Published: (2020-07-01)

First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research
by: Tomao F, et al.
Published: (2020-07-01)

Modern aspects of antiangiogenic therapy in ovarian cancer
by: A. A. Rumyantsev, et al.
Published: (2018-11-01)

Clinical case use bevacizumab for patient with metastatic ovarian cancer
by: M. R. Oganyan, et al.
Published: (2014-07-01)

The effectiveness of targeted therapy in the treatment of common forms of ovarian cancer
by: V V Saevets, et al.
Published: (2018-12-01)

PARP inhibitors in female reproductive system cancers
by: I A Pokataev, et al.
Published: (2017-06-01)

Selection of the anti-angiogenesis therapy for the first-line chemotherapy in advanced ovarian cancer
by: S V Khokhlova
Published: (2014-03-01)

Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence
by: Kazuho Nakanishi, et al.
Published: (2021-07-01)

Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with <i>BRCA1/2</i> Mutation: A Korean Multicenter Study
by: E Sun Paik, et al.
Published: (2019-11-01)

Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study
by: Maud Velev, et al.
Published: (2021-08-01)

First-line treatment of advanced ovarian cancer: an expert update
by: Branka Petrić-Miše
Published: (2020-01-01)

Health care professionals’ attitudes towards population-based genetic testing and risk-stratification for ovarian cancer: a cross-sectional survey
by: Katie E. J. Hann, et al.
Published: (2017-12-01)

Radiomic Analysis of MRI Images is Instrumental to the Stratification of Ovarian Cysts
by: Roxana-Adelina Lupean, et al.
Published: (2020-09-01)

Long-Term Follow-Up of a Female Patient Treated with Olaparib—Hope for a Long Life without Relapse?
by: Mateusz Kozłowski, et al.
Published: (2021-03-01)

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
by: McClung EC, et al.
Published: (2016-03-01)

Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses
by: A. G. Kedrova, et al.
Published: (2016-11-01)

Progression of choroidal metastasis of ovarian serous cystoadenocarcinoma after intravitreal bevacizumab treatment
by: Victor E. Reviglio, et al.
Published: (2013-02-01)

Cannot write session to /tmp/vufind_sessions/sess_qt3ve64gbvn8lbtpiv4hiqhrus